恆瑞醫藥(600276.SH):HRS-9821吸入混懸液獲批開展臨牀試驗
格隆匯8月23日丨恆瑞醫藥(600276.SH)公佈,近日,江蘇恆瑞醫藥股份有限公司收到國家藥品監督管理局核准簽發關於HRS-9821吸入混懸液的《藥物臨牀試驗批准通知書》,將於近期開展臨牀試驗。
HRS-9821可有效抑制呼吸道炎症、擴張支氣管,臨牀擬用於慢性阻塞性肺疾病(COPD)的維持治療。經查詢,目前國內外尚無同類產品獲批上市,亦無相關銷售數據。
截至目前,HRS-9821吸入混懸液相關項目累計已投入研發費用約2325萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.